Anal cancer: 국가별 선택지

European Union

• Retifanlimab (Zynyz) with carboplatin and paclitaxel[1]EMA authorisedNo biomarker requirement stated in fetched EMA news source; Adults with SCAC that cannot be removed by surgery and is metastatic or locally recurrent, in combination with carboplatin and paclitaxel. · The fetched EMA source is a recommendation/news page, not final EPAR product information; European Commission authorization status and member-state reimbursement must be verified separately. No claim is made for monotherapy EU use from this source. Confidence/conflicts: Medium-high for EMA CHMP recommendation; final authorization and country access remain follow-up gaps.
• Retifanlimab (Zynyz) with carboplatin and paclitaxel[1]EMA authorisedNo biomarker requirement stated in fetched EMA news source; Adults with SCAC that cannot be removed by surgery and is metastatic or locally recurrent, in combination with carboplatin and paclitaxel. · The fetched EMA source is a recommendation/news page, not final EPAR product information; European Commission authorization status and member-state reimbursement must be verified separately. No claim is made for monotherapy EU use from this source. Confidence/conflicts: Medium-high for EMA CHMP recommendation; final authorization and country access remain follow-up gaps.
• Retifanlimab (Zynyz) with carboplatin and paclitaxel[1]EMA authorisedNo biomarker requirement stated in fetched EMA news source; Adults with SCAC that cannot be removed by surgery and is metastatic or locally recurrent, in combination with carboplatin and paclitaxel. · The fetched EMA source is a recommendation/news page, not final EPAR product information; European Commission authorization status and member-state reimbursement must be verified separately. No claim is made for monotherapy EU use from this source. Confidence/conflicts: Medium-high for EMA CHMP recommendation; final authorization and country access remain follow-up gaps.